High doses of antiviral drug may be effective against Ebola

March 27, 2018, Public Library of Science
Ebola
Ebola virus. Credit: NIAID

High doses of favipiravir extended survival in non-human primates infected with Ebola virus, according to a new study published this week in PLOS Medicine by Jeremie Guedj of INSERM, France, and colleagues.

Despite repeated outbreaks in recent years, there is no effective treatment validated for patients with Ebola virus disease, which can kill about half of those infected. The antiviral drug favipiravir has been previously tested at lower doses in humans and was well-tolerated but did not show strong antiviral activity. In the current study, researchers infected 26 non-human primates with the 2001 Gabon strain of Ebola virus and followed them for 21 days. Thirteen animals were untreated and 13 were treated, beginning two days before infection, with twice daily doses of favipiravir at 100, 150, or 180 mg/kg.

All animals that were untreated or treated with 100 mg/kg of favipiravir died within 10 days of infection. Two out of 5 (40%) animals treated with 150 mg/kg were still alive at day 21 of the study, and 3 out of 5 animals (60%) treated with 180 mg/kg favipiravir survived to day 21. Moreover, the study showed that the drug inhibited viral replication in a drug concentration-dependent manner. However, applicability to humans is limited by the fact that this model is fully lethal and that treatment initiation in patients is most often initiated several days after infection, when symptoms and high levels of are already present, rather than before infection.

"These results, together with previous data collected on tolerance and pharmacokinetics in both and humans support the evaluation of high doses of favipiravir for future human intervention in particular for contact cases" the authors say.

Explore further: Antiviral favipiravir successfully treats Lassa virus in guinea pigs

More information: Guedj J, Piorkowski G, Jacquot F, Madelain V, Nguyen THT, Rodallec A, et al. (2018) Antiviral efficacy of favipiravir against Ebola virus: A translational study in cynomolgus macaques. PLoS Med 15(3): e1002535. doi.org/10.1371/journal.pmed.1002535

Related Stories

Antiviral favipiravir successfully treats Lassa virus in guinea pigs

October 13, 2015
Favipiravir, an investigational antiviral drug currently being tested in West Africa as a treatment for Ebola virus disease, effectively treated Lassa virus infection in guinea pigs, according to a new study from National ...

Limited promise in early results from Ebola drug trial

February 24, 2015
Early results from an Ebola trial using the experimental drug Avigan (favipiravir) showed Monday it was somewhat effective at saving lives if given early in the illness, but not later.

Nuanced findings for a large experimental treatment trial for Ebola virus disease

March 1, 2016
While not conclusive, valuable research generated through researching an experimental treatment for Ebola virus disease in Guinea during the recent Ebola outbreak will support future research into treating Ebola virus disease, ...

Japan ready to offer flu drug for Ebola treatment (Update)

August 25, 2014
Japan said Monday it is ready to provide a Japanese-developed anti-influenza drug as a possible treatment for the rapidly expanding Ebola outbreak.

Researchers develop Ebola treatment effective three days after infection

April 22, 2015
Researchers from The University of Texas Medical Branch at Galveston and Tekmira Pharmaceuticals Corp., have successfully developed a post-exposure treatment that is effective against a specific strain of the Ebola virus ...

Drug targeting Ebola virus protein VP24 shows promise in monkeys

February 10, 2015
An experimental medication that targets a protein in Ebola virus called VP24 protected 75% of a group of monkeys that were studied from Ebola virus infection, according to new research conducted by the U.S. Army, in collaboration ...

Recommended for you

Research finds new mechanism that can cause the spread of deadly infection

April 20, 2018
Scientists at the University of Birmingham have discovered a unique mechanism that drives the spread of a deadly infection.

Selection of a pyrethroid metabolic enzyme CYP9K1 by malaria control activities

April 20, 2018
Researchers from LSTM, with partners from a number of international institutions, have shown the rapid selection of a novel P450 enzyme leading to insecticide resistance in a major malaria vector.

Study predicts 2018 flu vaccine will have 20 percent efficacy

April 19, 2018
A Rice University study predicts that this fall's flu vaccine—a new H3N2 formulation for the first time since 2015—will likely have the same reduced efficacy against the dominant circulating strain of influenza A as the ...

Low-cost anti-hookworm drug boosts female farmers' physical fitness

April 19, 2018
Impoverished female farm workers infected with intestinal parasites known as hookworms saw significant improvements in physical fitness when they were treated with a low-cost deworming drug. The benefits were seen even in ...

Zika presents hot spots in brains of chicken embryos

April 19, 2018
Zika prefers certain "hot spots" in the brains of chicken embryos, offering insight into how brain development is affected by the virus.

Super-superbug clones invade Gulf States

April 18, 2018
A new wave of highly antibiotic resistant superbugs has been found in the Middle East Gulf States, discovered by University of Queensland researchers.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.